KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Globus Medical (GMED) Research & Development (2016 - 2025)

Globus Medical (GMED) has disclosed Research & Development for 15 consecutive years, with $36.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 8.25% year-over-year to $36.2 million, compared with a TTM value of $147.2 million through Dec 2025, up 23.65%, and an annual FY2025 reading of $147.2 million, down 10.08% over the prior year.
  • Research & Development was $36.2 million for Q4 2025 at Globus Medical, down from $38.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $52.3 million in Q4 2023 and bottomed at $12.6 million in Q1 2024.
  • Average Research & Development over 5 years is $28.0 million, with a median of $25.3 million recorded in 2023.
  • The sharpest move saw Research & Development surged 234.77% in 2021, then crashed 61.77% in 2022.
  • Year by year, Research & Development stood at $51.0 million in 2021, then plummeted by 61.77% to $19.5 million in 2022, then skyrocketed by 167.86% to $52.3 million in 2023, then crashed by 36.06% to $33.4 million in 2024, then rose by 8.25% to $36.2 million in 2025.
  • Business Quant data shows Research & Development for GMED at $36.2 million in Q4 2025, $38.1 million in Q3 2025, and $40.0 million in Q2 2025.